Search Results - Pennell, D.
- Showing 1 - 4 results of 4
-
1
Continued improvement and normalization of myocardial T2*in patients with beta-thalassemia major treated with deferasirox (Exjade (R)) for up to 3 years by Pennell, D., Porter, J.B., Cappellini, M.D., Chan, L.L., El-Beshlawy, A., Aydinok, Y., Ibrahim, H., Li, Chi-Kong, Viprakasit, V., Elalfy, M.S., Kattamis, A., Smith, G., Habr, D., Domokos, G., Roubert, B., Taher, A.
Published 2010Get full text
Article -
2
Continued improvement in cardiac T2*with deferasirox treatment over 2 years: Results from the extension of epic cardiac substudy in beta-thalassaemia patients with myocardial sider... by Pennell, D., Porter, J., Cappellini, M., Chan, L.L., El-Beshlawy, A., Aydinok, Y., Ibrahim, H., Li, C.K., Viprakasit, V., Elalfy, M., Kattamis, A., Smith, G., Habr, D., Roubert, B., Taher, A.
Published 2010Get full text
Article -
3
Deferasirox effectively removes cardiac iron in beta-thalassaemia patients with myocardial siderosis previously chelated with deferoxamine monotherapy or deferoxamine-deferiprone t... by Pennell, D., Porter, J., Cappellini, M., Chan, L.L., El-Beshlawy, A., Aydinok, Y., Ibrahim, H., Li, C.K., Viprakasit, V., Elalfy, M., Kattamis, A., Smith, G., Habr, D., Roubert, B., Taher, A.
Published 2010Get full text
Article -
4
Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia by Pennell, D.J., Porter, J.B., Cappellini, M.D., El-Beshlawy, A., Chan, L.L., Aydinok, Y., Elalfy, M.S., Sutcharitchan, P., Li, C.K., Ibrahim, H., Viprakasit, V., Kattamis, A., Smith, G., Habr, D., Domokos, G., Roubert, B., Taher, A.
Published 2010Get full text
Article
